Literature DB >> 11136382

Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders.

S Solovieva1.   

Abstract

A questionnaire-based follow-up study of 150 Finnish patients with coagulation disorders was conducted to evaluate the changes in clinical manifestation of the disease, pain intensity, functional disability and patient's health-related quality of life, occurring during a 3-year period. Health-related quality of life was assessed using the MOS-36 health survey. The clinical severity of the disease manifestation was estimated using the frequency of bleeding episodes into joints and soft tissue during the previous 12 months. Severity of musculoskeletal morbidity, which reflects simultaneous presence of pain and disability, was estimated using intensity of pain and level of disability. Results showed that clinical severity of the disease remained unchanged during the 3-year period for the majority of patients. Nonetheless, the annual number of bleeds in patients with severe or moderately severe haemophilia was still disconcertingly high and the number of bleeding episodes into soft tissue had increased. The clinical severity of the disease manifestation, rather than the severity of the disease based on molecular classification, was a factor that negatively influenced the intensity of pain (both acute and chronic), as well as level of disability. Severity of musculoskeletal morbidity at time 1 and changes in severity of musculoskeletal morbidity over time were found to be significant predictors of physical role, bodily pain, vitality and social functioning. In conclusion, the disease can be relatively well controlled by the availability of coagulation products, thus stabilizing the clinical severity of the disease manifestation during the 3-year period studied. The findings stress the importance of preventing haemorrhages to avoid resulting permanent joint impairment and disability.

Entities:  

Mesh:

Year:  2001        PMID: 11136382     DOI: 10.1046/j.1365-2516.2001.00476.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

Review 1.  Quality of life in rare genetic conditions: a systematic review of the literature.

Authors:  Julie S Cohen; Barbara B Biesecker
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

2.  Longitudinal changes in health-related quality of life for chronic diseases: an example in hemophilia A.

Authors:  Jiat-Ling Poon; Jason N Doctor; Michael B Nichol
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

3.  Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life.

Authors:  C Rae; W Furlong; J Horsman; E Pullenayegum; C Demers; J St-Louis; D Lillicrap; R Barr
Journal:  Haemophilia       Date:  2012-09-21       Impact factor: 4.287

4.  Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand's disease.

Authors:  Igor Govorov; Lena Ekelund; Roza Chaireti; Petra Elfvinge; Margareta Holmström; Katarina Bremme; Miriam Mints
Journal:  Exp Ther Med       Date:  2016-03-10       Impact factor: 2.447

5.  Quality of Life, Perception of Disease and Coping Strategies in Patients with Hemophilia in Spain and El Salvador: A Comparative Study.

Authors:  Rubén Cuesta-Barriuso; Ana Torres-Ortuño; Joaquín Nieto-Munuera; José Antonio López-Pina
Journal:  Patient Prefer Adherence       Date:  2021-08-21       Impact factor: 2.711

6.  Assessing quality of life in individuals with hereditary blood coagulation disorders.

Authors:  S Solovieva; N Santavirta; S Santavirta; Y T Konttinen
Journal:  Qual Life Res       Date:  2004-06       Impact factor: 4.147

7.  Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries.

Authors:  Ernesto Cimino; Silvia Linari; Mara Malerba; Susan Halimeh; Francesca Biondo; Martina Westfeld
Journal:  Patient Prefer Adherence       Date:  2014-12-12       Impact factor: 2.711

8.  The Cost of Von Willebrand Disease in Europe: The CVESS Study.

Authors:  George Morgan; Sarah Brighton; Mike Laffan; Jenny Goudemand; Bethany Franks; Alan Finnegan
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

9.  Psychometric properties of the Greek Haem-A-QoL for measuring quality of life in Greek haemophilia patients.

Authors:  Agoritsa Varaklioti; Nick Kontodimopoulos; Olga Katsarou; Dimitris Niakas
Journal:  Biomed Res Int       Date:  2014-05-06       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.